The 50-day moving average for BRNS moved above the 200-day moving average on September 28, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Momentum Indicator moved above the 0 level on September 22, 2026. You may want to consider a long position or call options on BRNS as a result. In 98 of 116 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 22 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Aroon Indicator for BRNS entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.530) is normal, around the industry mean (2.973). P/E Ratio (-0.726) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (2.165) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. BRNS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BRNS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The RSI Oscillator for IMNN moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 57 similar instances when the indicator left oversold territory. In 45 of the 57 cases the stock moved higher. This puts the odds of a move higher at 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 76 cases where IMNN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on IMNN as a result. In 70 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for IMNN just turned positive on October 21, 2026. Looking at past instances where IMNN's MACD turned positive, the stock continued to rise in 37 of 50 cases over the following month. The odds of a continued upward trend are 74%.
Following a +23.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMNN advanced for three days, in 128 of 178 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
IMNN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMNN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IMNN entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.675) is normal, around the industry mean (2.973). P/E Ratio (-0.428) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. IMNN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMNN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IMNN | ||
|---|---|---|
OUTLOOK RATING 1..100 | 3 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 87 | |
P/E GROWTH RATING 1..100 | 16 | |
SEASONALITY SCORE 1..100 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| BRNS | IMNN | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 79% |
| Stochastic ODDS (%) | 2 days ago 83% | 1 day ago 75% |
| Momentum ODDS (%) | 1 day ago 84% | 1 day ago 71% |
| MACD ODDS (%) | N/A | 1 day ago 74% |
| TrendWeek ODDS (%) | 1 day ago 78% | 1 day ago 72% |
| TrendMonth ODDS (%) | 1 day ago 77% | 1 day ago 90% |
| Advances ODDS (%) | N/A | 1 day ago 72% |
| Declines ODDS (%) | N/A | 4 days ago 90% |
| BollingerBands ODDS (%) | N/A | 1 day ago 77% |
| Aroon ODDS (%) | 1 day ago 88% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BRNS’s FA Score shows that 0 FA rating(s) are green while IMNN’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BRNS’s TA Score shows that 2 TA indicator(s) are bullish while IMNN’s TA Score has 6 bullish TA indicator(s).
BRNS (@Biotechnology) experienced а 0.00% price change this week, while IMNN (@Biotechnology) price change was +17.92% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
BRNS is expected to report earnings on Nov 05, 2026.
IMNN is expected to report earnings on Nov 12, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, BRNS has been loosely correlated with NGNE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if BRNS jumps, then NGNE could also see price increases.
| Ticker / NAME | Correlation To BRNS | 1D Price Change % | ||
|---|---|---|---|---|
| BRNS | 100% | N/A | ||
| NGNE - BRNS | 51% Loosely correlated | -6.90% | ||
| NEUP - BRNS | 50% Loosely correlated | N/A | ||
| TARA - BRNS | 35% Loosely correlated | -2.40% | ||
| BGMS - BRNS | 31% Poorly correlated | -5.62% | ||
| ARGX - BRNS | 29% Poorly correlated | -1.61% | ||
More | ||||
A.I.dvisor indicates that over the last year, IMNN has been loosely correlated with ABVX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if IMNN jumps, then ABVX could also see price increases.
| Ticker / NAME | Correlation To IMNN | 1D Price Change % | ||
|---|---|---|---|---|
| IMNN | 100% | +5.04% | ||
| ABVX - IMNN | 58% Loosely correlated | -3.49% | ||
| REPL - IMNN | 57% Loosely correlated | +2.30% | ||
| DNLI - IMNN | 30% Poorly correlated | -0.11% | ||
| BRNS - IMNN | 29% Poorly correlated | N/A | ||
| IVVD - IMNN | 28% Poorly correlated | -4.57% | ||
More | ||||